H Lundbeck AS (HLUNa)

Copenhagen
Currency in DKK
34.20
-0.40(-1.16%)
Real-time Data
HLUNa Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
Fair Value
Day's Range
33.5534.70
52 wk Range
27.1041.70
Key Statistics
Edit
Prev. Close
34.6
Open
34.1
Day's Range
33.55-34.7
52 wk Range
27.1-41.7
Volume
69.75K
Average Volume (3m)
67.08K
1-Year Change
17.05%
Book Value / Share
25.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HLUNa Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

H Lundbeck B Company Profile

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. The company was founded in 1915 and is headquartered in Valby, Denmark.

Employees
5707
Market
Denmark

Compare HLUNa to Peers and Sector

Metrics to compare
HLUNa
Peers
Sector
Relationship
P/E Ratio
12.6x17.7x−0.6x
PEG Ratio
0.350.080.00
Price/Book
1.6x4.4x2.6x
Price / LTM Sales
1.8x3.9x3.1x
Upside (Analyst Target)
-8.9%48.8%
Fair Value Upside
Unlock−1.0%7.5%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.17
Dividend Yield
2.02%
Industry Median 1.03%
Annualised payout
0.7000
Paid annually
5-Years Growth
+2.99%
Growth Streak

Earnings

Latest Release
May 10, 2023
EPS / Forecast
0.89 / --
Revenue / Forecast
5.04B / --
EPS Revisions
Last 90 days

People Also Watch

0.1286
APE
+1.42%
80.08
BALDb
-0.20%
35.20
SNL
-0.14%
0.371
NXTE
+0.82%
133.40
TRIA
+0.23%

FAQ

What Is the H Lundbeck B (HLUNa) Stock Price Today?

The H Lundbeck B stock price today is 34.20

What Stock Exchange Does H Lundbeck B Trade On?

H Lundbeck B is listed and trades on the Copenhagen stock exchange.

What Is the Stock Symbol for H Lundbeck B?

The stock symbol for H Lundbeck B is "HLUNa."

Does H Lundbeck B Pay Dividends? What’s The Current Dividend Yield?

The H Lundbeck B dividend yield is 2.02%.

What Is the H Lundbeck B Market Cap?

As of today, H Lundbeck B market cap is 41.11B.

What is H Lundbeck B Earnings Per Share?

The H Lundbeck B EPS is 3.17.

From a Technical Analysis Perspective, Is HLUNa a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.